Medarex is building the ultimate monoclonal antibody. Its UltiMAb technology utilizes transgenic mice whose antibody gene expression is suppressed to create fully human monoclonal antibodies (single-source proteins). Medarex has more than 40 antibodies for cancer, rheumatoid arthritis, and other autoimmune, inflammatory, and infectious diseases in clinical trials or pre-trial stages. The company has partnerships with numerous pharma and biotech firms including Genmab, which has licensed antibody therapies for leukemia, arthritis, and other conditions. Other development partners include Pfizer, Amgen, Eli Lilly, and Kirin. Another major collaborator, Bristol-Myers Squibb, acquired Medarex for $2.4 billion in 2009.

Simcere Pharmaceutical Group was founded in 1995 and is headquartered in Nanjing, the People's Republic of China. Simcere Pharmaceutical Group is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. The Company has introduced a generic anti-stroke medication under the brand name Bicun, a 5-FU sustained release implant under the brand name Sinofuan and an anti-cancer medication under the brand name Endu. It manufactures and sells 45 principal pharmaceutical products and is the distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under its brand names. On May 5, 2008, it acquired 70% interest in Wuhu Zhong Ren Pharmaceutical Co., Ltd. (Wuhu Simcere Zhong Ren). On January 6, 2009, Simcere Pharmaceutical Group acquired the remaining 10% of interest of Shandong Simcere Medgenn Bio-Pharmaceutical Co., Ltd. (Shandong Simcere).

Actelion Ltd is a Swiss biopharmaceutical company with a global presence that focuses on the discovery, development and commercialization of treatments to serve unmet medical needs. Its products specialize in conditions related to the endothelium, the single layer of cells separating every blood vessel from the blood stream. The Company has three approved drugs on the market. Tracleer, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension, a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. The second product, Zavesca, was in-licensed from Oxford GlycoSciences. Zavesca is an approved oral treatment for type 1 Gaucher disease, a rare debilitating metabolic disorder. Ventavis, the third product, is an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation, among other benefits.

Contract Pharmacal Corp. (CPC) is a full-service contract research organization serving pharmaceutical companies, retailers, and wholesalers worldwide. CPC manufactures dietary supplements, a variety of over-the-counter medications, and private label and generic prescription drugs. The company's prescription portfolio consists of mostly of prenatal and multi-vitamins, as well as urinary tract infection treatments. Production capabilities also include manufacturing tablets, gelatin capsules, softgels, and liquids that can be packaged in bottles, cans, blister pouches, and cartons. CPC (in business since 1971) is owned and operated by CEO Matt Wolf and the founding Wolf family.

Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas. Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. Its lead drug includes Proellex, a selective blocker of the progesterone receptor, which is in Phase III clinical trials for use as a pre-surgical treatment for women with anemia due to excessive menstrual bleeding associated with uterine fibroids, or anemia associated with uterine fibroids; in Phase III clinical trials for the chronic treatment of symptoms associated with uterine fibroids; and in Phase II clinical trials for the chronic treatment of symptoms associated with endometriosis. The company's product candidates also comprise Androxal, a single isomer of clomiphene citrate, which is in Phase IIb clinical trials for the treatment of low testosterone levels in men, who want to improve or maintain their fertility and/or sperm number and function. In addition, it holds a patent portfolio of phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction under the Z-Max brand name. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics Inc. in May 2006 to reflect company's focus on therapeutics for reproductive disorders.

BioTime, Inc. company was founded in 1990 and is headquartered in Alameda, California. BioTime, Inc. is a biomedical organization engaged in the development of synthetic plasma expanders and blood volume substitute solutions for use in surgery, trauma care, organ transplant procedures, and other areas of medicine. The Company’s operating revenues have been generated primarily from licensing fees related to the sale of its plasma volume expander products, primarily Hextend. The company began to make its first stem cell research products available during the year ended December 31, 2008, but it had not yet generated significant revenues in that business segment.

Greer Laboratories, Inc. company develops and manufactures a variety of allergy immunotherapy testing and treatment materials. Greer operates through four business units: Human; Veterinary; Source Materials; and Contract Development. Greer Laboratories company's products include allergenic extracts, vials, single and multiple skin testing devices, and safety syringes, as well as source materials used for allergy testing such as dust mites, venoms, dander, molds, insects, and pollen. Greer Laboratories company began operations in 1904.

Ranbaxy Pharmaceuticals Inc. company, the US arm of Indian generic pharmaceuticals giant Ranbaxy Laboratories Limited, makes and markets about 50 generic and over-the-counter (OTC) drugs. It accounts for about a quarter of its parent's annual revenues. RPI's generic offerings, produced by manufacturing subsidiary Ohm Laboratories, include anti-infectives and treatments for cardiovascular, gastrointestinal, and central nervous system disorders. Its OTC products include analgesics, antihistamines, and decongestants. Sister subsidiary Ranbaxy Laboratories, Inc. (RLI) develops branded pharmaceuticals.

Life Technologies Corporation operates as a global biotechnology tools company focused on improving the human condition. Its systems, consumables, and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that better the quality of life. Life Technologies' customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. The company delivers a range of products and services, including systems, instruments, reagents, and custom services. Its portfolio of products includes technologies for capillary electrophoresis based sequencing, next generation sequencing, mass spectrometry, sample preparation, cell culture, RNA interference analysis, functional genomics research, proteomics, and cell biology applications, as well as clinical diagnostic applications and water testing analysis. The company has a presence in approximately 100 countries, and possesses a growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems, Inc. It has a strategic alliance agreement with Applied Biosystems designed to accelerate research into complex diseases and medical conditions; and strategic scientific research collaboration with The University of Queensland's Institute for Molecular Bioscience to study pancreatic and ovarian cancer in Australia. The company is based in Carlsbad, California.

NextGen Group, which does business as NextGen Sciences, puts proteins to the test. The research and development company provides protein analysis services for biotechnology and pharmaceutical customers around the world. Specific services include biomarker discovery and assay development, which are often used in the drug development process to test preclinical and clinical samples for therapeutic efficacy and safety. NextGen's biomarker projects focus on Alzheimer's disease and oncology, among other therapeutic areas. The group has operations in the US and the UK.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.